NCT06877624View on ClinicalTrials.gov

A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

May 15, 2025

Study Completion Date

May 15, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

QRL-101

This cross-over design study will evaluate three formulations (Formulations 1, 2, and 3) of QRL-101, beginning in a fasted condition before moving to a fed cross-over design.

Trial Locations (1)

9728 NZ

ICON plc. Van Swietenlaan 6, Groningen

All Listed Sponsors
lead

QurAlis Corporation

INDUSTRY

NCT06877624 - A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants | Biotech Hunter | Biotech Hunter